Take a quantum leap towards your next blockbuster.
There are no more low-hanging fruit in drug discovery.
It’s time to use a taller ladder.
Leap over the hurdles of conventional drug discovery
Our QuADD (Quantum-Aided Drug Design) solutions make it possible for computational chemistry teams to explore vast chemical spaces and optimize drug candidates in a fraction of the time required by conventional methods and tools.
Uncover novel and diverse hard-to-find molecules
All of our solutions integrate seamlessly into your discovery pipeline, allowing your team to apply your preferred discovery strategy.
- Best-In-Class Mode: Prioritize similarity
to template structure. - First-In-Class Mode Prioritize novelty.
- Preferred-Library Mode: Limit your search to your choice of commercial libraries.
- Scaffold-Hopping Mode: Hold part of the molecule constant while exploring other parts.
Apply to any protein target — no training data required
Unlike AI solutions that are constrained by available training data, our quantum-aided solutions use physics-based calculations — which can be used to identify and optimize drug candidates for any drug target with a known 3D structure, including those that are novel and less studied.
Maintain explainability and confidence as you search uncharted spaces
Our QuADD solutions apply physics-based models that provide explainable output, delivering results that chemists can clearly understand and trust.
Supercharge your drug design pipeline with quantum computing power
What our customers are saying
“Our collaboration with PolarisQB led to rapid identification of viable drug candidates, significantly accelerating our research timeline towards quality solutions for hard to tackle or neglected diseases affecting women’s health.”
“Using quantum computing and advanced AI technology with PolarisQB, we explored a chemical space that was previously undefined, leading to the discovery of novel molecules for our primary program of Optimizing the Aging and Longevity Molecular Process much faster than expected.”
“This partnership represents the ultimate ambition for collaboration between biology and technology, where the full diversity of newly identified disease targets can be married to the most logical and rapid method of finding small molecule drugs.”
